Pharmaceuticals & Therapeutics

Promising Phase 3 data reveals a novel, organ-sparing laser therapy for a rare cancer, signaling a potential paradigm shift away from radical surgery.

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

SkinSpirit's new Princeton clinic isn't just an expansion; it's a strategic move in the booming medical aesthetics market. Here's why it matters.

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.